Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor
ABL1 TKIs. When planning a pregnancy, it is also necessary to take the patients' backgrounds, disease states, and medical history into account.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 64(2023), 2 vom: 10., Seite 102-106 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Shodai, Aya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.64.102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35495668X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35495668X | ||
| 003 | DE-627 | ||
| 005 | 20231227131201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.64.102 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM35495668X | ||
| 035 | |a (NLM)36990728 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Shodai, Aya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A tyrosine kinase inhibitor (TKI) was used to treat the patient, a 35-year-old woman who was diagnosed with chronic myeloid leukemia at the age of 22 years. Since a four-year deep molecular response (DMR) was obtained, spontaneous pregnancy was planned under TKI withdrawal. Even though her disease had advanced to MR2.0 at the time of pregnancy confirmation, 2 months from TKI cessation, interferon α therapy was initiated in light of the patient's history. Later, the patient reached MR3.0, gave birth to a healthy baby, and maintained MR3.0-4.0. TKI was resumed after about 6 months of breastfeeding. Treatment-free remission (TFR) is required for natural conception despite the teratogenicity and miscarriage risks associated with BCR::ABL1 TKIs. When planning a pregnancy, it is also necessary to take the patients' backgrounds, disease states, and medical history into account | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a Interferon α | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 650 | 7 | |a Tyrosine Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Tazaki, Yukiko |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Natsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Hamada, Tomonori |e verfasserin |4 aut | |
| 700 | 1 | |a Akahoshi, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Ueno, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Tabuchi, Tomohisa |e verfasserin |4 aut | |
| 700 | 1 | |a Arima, Naosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashida, Maiko |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimitsu, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ishitsuka, Kenji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 64(2023), 2 vom: 10., Seite 102-106 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2023 |g number:2 |g day:10 |g pages:102-106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.64.102 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2023 |e 2 |b 10 |h 102-106 | ||